The study of Sun et al. further suggests that the C-terminus of A2BAR potentially provides a target for developing peptidemimetic drugs that block NFκB signaling, which could be used for treating NFκB-related diseases such as inflammation and cancer (Sun et al., 2012). Here, NFKB1 is linked to cancer.